查菲埃立克體IgG免疫熒光玻片試劑盒

Ehrlichia chaffeensis IgG 120-test IFA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測(cè)人血清中的查菲埃立克體 IgG 抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

包括包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲(chóng)病、立克次體、果氏巴貝西蟲(chóng)、馬焦蟲(chóng)、牛焦蟲(chóng)、利什曼蟲(chóng)、新包蟲(chóng)、弓形蟲(chóng)、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

查菲埃立克體IgG免疫熒光玻片試劑盒

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

研究還發(fā)現(xiàn)，這種抗體能夠遏制胰腺癌、肺癌、抗原抗體癌、大腸癌、前列腺癌等癌細(xì)胞增殖。
研究人員指出，血液中的抗體與核糖體蛋白L29結(jié)合后，能夠遏制后者的功能，使癌細(xì)胞難以分裂，從而凋亡，因此這種抗體應(yīng)該就是構(gòu)成人體內(nèi)腫瘤免疫系統(tǒng)的物質(zhì)之一。目前他們正在研發(fā)以這種抗體為基礎(chǔ)的抗癌藥物和疫苗。
道格拉斯·梅爾頓比任何人都急于得到糖尿病的治愈方法，因?yàn)樗膬鹤釉谶€是個(gè)嬰兒的時(shí)候就患有此病了，而他的女兒在14歲時(shí)被診斷出該病。在過(guò)去20年中的大多數(shù)時(shí)間，哈佛干細(xì)胞研究所的發(fā)育生物學(xué)家道格拉斯·梅爾頓一直將他的研究致力于該病的治愈方法的發(fā)現(xiàn)。他和他的同事在本周報(bào)告了接近這個(gè)目標(biāo)的重要的一步：一個(gè)配方可以把人類(lèi)干細(xì)胞轉(zhuǎn)變?yōu)楣δ苄砸葝uβ細(xì)胞——該細(xì)胞可被1型糖尿病患者(如梅爾頓的兒子和女兒)自身的免疫系統(tǒng)破壞。研究人員在本研究中轉(zhuǎn)變出的胰島β細(xì)胞通過(guò)產(chǎn)生胰島素對(duì)葡萄糖作出反應(yīng)，如同正常β細(xì)胞所做的。當(dāng)將糖尿病的形式注入到小鼠中，該細(xì)胞可以治愈這個(gè)疾病。
“糖尿病研究界為這種類(lèi)型的突破已經(jīng)等了好長(zhǎng)一段時(shí)間，” 倫敦帝國(guó)學(xué)院研究β細(xì)胞遺傳的豪爾赫·費(fèi)雷爾說(shuō)。這個(gè)實(shí)驗(yàn)室生成的細(xì)胞可能會(huì)成為用于研究糖尿病的一種有價(jià)值的工具，并且梅爾頓希望，其zui終可以用來(lái)治療患者。

The study also found that this antibody can curb pancreatic cancer, lung cancer, antigen-antibody cancer, colorectal cancer, prostate cancer and other cancer cell proliferation.
The researchers pointed out that the blood of antibodies and ribosomal protein L29 binding, the ability to contain the latter, so that cancer cells are difficult to divide, and thus apoptosis, so this antibody should constitute one of the body's tumor immune system substances. They are currently developing anti-cancer drugs and vaccines based on this antibody.
Douglas Melton is more eager than anyone to get a cure for diabetes because his son was ill when he was still a baby and his daughter was diagnosed at the age of 14. For most of the past two decades Douglas Melton, a developmental biologist at the Harvard Stem Cell Institute, has been devoting his research to the discovery of a cure for the disease. This week, he and his colleagues reported an important step closer to achieving this goal: a formula that converts human stem cells into functional islet beta cells that can be activated by type 1 diabetics (such as Melton's son and daughter Own immune system damage. The islet beta cells that the researchers transformed in this study respond to glucose by producing insulin, as does normal beta cells. When a form of diabetes is injected into mice, the cell can heal the disease.
"The diabetes community has waited for this type of breakthrough for a long time," said Jorge Ferrer, who studies beta-cell inheritance at Imperial College London. The lab-generated cells may be a valuable tool for studying diabetes and Melton hopes it can eventually be used to treat patients.